Skin photoaging or skin photodamage were terms used to describe the change in the structure, function and appearance of skin caused by prolonged and repeated exposure to sunlight or other ultraviolet light sources. The visible effects of skin photodamage were fine lines, skin sagging, skin roughness, liver spots and also the appearance of red patches made up of thin red vessels (called telangiectasia). More and more people were presenting to doctors with concerns about skin photodamage and the demand for corrective procedures was increasing. Metvix photodynamic therapy (Metvix PDT) is a procedure currently marketed in several countries in Europe (including the United Kingdom \[UK\] and Spain) and in Australia, for the treatment of benign forms of skin cancer (example, actinic keratosis). The aim of the study was to assess whether Metvix PDT would be effective in correcting the effects related to photodamage and whether it would be well tolerated.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Severity of Photodamage
Timeframe: At Week 20
Number of Participants With Severity of Mottled Hyper-Pigmentation
Timeframe: At Week 20
Number of Participants With Severity of Fine Lines
Timeframe: At Week 20
Number of Participants With Severity of Telangiectasia
Timeframe: At Week 20
Number of Participants With Severity of Skin Roughness
Timeframe: At Week 20
Number of Participants With Severity of Skin Laxity
Timeframe: At Week 20
Number of Participants With Tolerability Assessment of Erythema
Timeframe: At Week 20
Number of Participants With Tolerability Assessment of Edema
Timeframe: At Week 20
Number of Participants With Tolerability Assessment of Oozing/Crusting
Timeframe: At Week 20
Participant's Skin Discomfort Score Using Visual Analogue Scale (VAS)
Timeframe: At Week 4
Participant's Skin Discomfort Score Using Visual Analogue Scale (VAS)
Timeframe: At Week 8
Number of Participants With Tolerability Assessment of Scaling
Timeframe: At Week 20
Number of Participants With Adverse Events (AEs)
Timeframe: Up to Week 20